Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), has appointed Yuk Chun Chiu as vice president of manufacturing operations. Chiu will serve on the Senior Leadership Team and report to Dr. Jesse McCool, CEO of Cytovance Biologics.
 
"I am thrilled to be welcoming Yuk to my Senior Leadership Team in Oklahoma City.  He and I worked together about ten years ago and I have seen his leadership, technical expertise and commitment to continuous improvement strengthen an organization," McCool stated. "Yuk's deep background in commercial manufacturing will be critical to advancing our maturing project pipeline of recombinant proteins and gene therapies and help keep Cytovance tethered to the cutting edge of our industry."
 
In this role, Chiu will be responsible for directing manufacturing operations MST, supply chain, engineering and facilities. Chiu will lead a team that supports efficient and collaborative manufacturing operations that ensure our customers reach their development goals enabling positive outcomes for patients.
 
Chiu brings 18 years of industry experience where he most recently served as director of manufacturing and engineering at AstraZeneca and group head of process analytical technology at Bayer. He is an active member of the International Society of Pharmaceutical Engineering where he holds different positions for multiple CoP Steering Committees. Chiu holds a Bachelor of Science degree in Chemical Engineering and a Master’s degree in Pharmaceutical Engineering, both through the University of Michigan – Ann Arbor.